What is the impact of osteoporosis education and bone mineral density testing for postmenopausal women in a managed care setting?
- 1 March 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Menopause
- Vol. 8 (2) , 141-148
- https://doi.org/10.1097/00042192-200103000-00010
Abstract
To assess whether osteoporosis education, with and without bone mineral density (BMD) testing, increases the initiation of lifestyle changes and pharmaceutical treatment to prevent osteoporosis. A total of 508 women, aged 54–65, from a large managed care organization who were not on osteoporosis prevention therapy participated in an intervention study. Participants were randomly assigned to either an education class on osteoporosis (n = 301) or education plus BMD (n = 207). A control group of 187 women receiving no intervention were also surveyed to serve as comparison. Group differences and differences based on BMD test result were compared 6 months after education regarding self-reported changes in health behaviors using χ2 tests and logistic regression analyses. Of the 508 intervention participants, 455 (90%) responded to the follow-up survey. Initiation of hormone replacement therapy was reported by 9%, with 5% reporting starting alendronate. More than half reported changes in diet, exercise, or calcium intake. Forty-three percent increased their vitamin D intake. There were no significant group differences in behavior except with regard to pharmaceutical therapy; subjects with education plus BMD were three times more likely than those receiving education only to report starting hormone replacement therapy (p = 0.004). Low BMD scores were associated with increasing vitamin D intake (p = 0.03) and starting medication (p = 0.001). Women in the intervention groups were significantly more likely to report modifying their diet (p p Education regarding osteoporosis prevention seems to encourage women to make lifestyle changes. The inclusion of BMD testing enhances the likelihood that women will consider pharmaceutical therapy.Keywords
This publication has 18 references indexed in Scilit:
- Alendronate and Estrogen–Progestin in the Long-Term Prevention of Bone Loss: Four-Year Results from the Early Postmenopausal Intervention Cohort Study: A Randomized, Controlled TrialAnnals of Internal Medicine, 1999
- Vertebral Fractures and Mortality in Older WomenArchives of internal medicine (1960), 1999
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJAMA, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Epidemiology and predictors of fractures associated with osteoporosisThe American Journal of Medicine, 1997
- Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo StudyPublished by American Medical Association (AMA) ,1997
- Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis FoundationJournal of Bone and Mineral Research, 1997
- Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPIPublished by American Medical Association (AMA) ,1996
- Costs and health effects of osteoporotic fracturesBone, 1994
- Consensus development conference: prophylaxis and treatment of osteoporosisThe American Journal of Medicine, 1991